Servizio momentaneamente sospeso per manutenzione.


Personale Strutture


Professore Ordinario






Orari di ricevimento

  • presso Studio, Edificio B Dipartimento Scienze del Farmaco
    Mandare una email per richiedere un appuntamento


1. Cilurzo F, Cristiano MC, Da Pian M, Cianflone E, Quintieri L, Paolino D, Pasut G. Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine. Anticancer Agents Med Chem. 2019 (accepted)
2. Maso K, Monia Montagner I, Grigoletto A, Schiavon O, Rosato A, Pasut G. A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs. Eur J Pharm Biopharm. 2019:S0939-6411(19)30399-6
3. Wahlich J, Desai A, Greco F, Hill K, Jones AT, Mrsny RJ, Pasut G, Perrie Y, Seib FP, Seymour LW, Uchegbu IF. Nanomedicines for the Delivery of Biologics. Pharmaceutics. 2019;11(5): E210
4. Catanzaro D, Nicolosi S, Cocetta V, Salvalaio M, Pagetta A, Ragazzi E, Montopoli M, Pasut G. (2018) Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. ONCOTARGET vol. 9, p. 16847-16860
5. Grigoletto Antonella, Mero Anna, Yoshioka Hiroki, Schiavon Oddone, Pasut Gianfranco. (2017). Covalent immobilisation of transglutaminase: stability and applications in protein PEGylation. JOURNAL OF DRUG TARGETING, vol. 25, p. 317-346
6. Montagner Isabella Monia, Merlo Anna, Carpanese Debora, Dalla Pietà Anna, Mero Anna, Grigoletto Antonella, Loregian Arianna, Renier Davide, Campisi Monica, Zanovello Paola, Pasut Gianfranco, Rosato Antonio (2016). A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer. JOURNAL OF CONTROLLED RELEASE, vol. 236, p. 79-89
7. Grigoletto Antonella, Mero Anna, Zanusso Ilenia, Schiavon Oddone, Pasut Gianfranco (2016). Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates. MACROMOLECULAR BIOSCIENCE, vol. 16, p. 50-56
8. Antonella Grigoletto, Katia Maso, Anna Mero, Antonio Rosato, Oddone Schiavon, Gianfranco Pasut (2016). Drug and protein delivery by polymer conjugation. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol. 32, p. 132-141
9. Pasut Gianfranco, Panisello Arnau, Folch-Puy Emma, Lopez Alexandre, Castro-Benítez Carlos, Calvo Maria, Carbonell Teresa, García-Gil Agustín, Adam René, Roselló-Catafau Joan (2016). Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury. WORLD JOURNAL OF GASTROENTEROLOGY, vol. 22, p. 6501-6508
10. Mero A., Grigoletto A., Maso K., Yoshioka H., Rosato A., Pasut G. (2016). Site-selective enzymatic chemistry for polymer conjugation to protein lysine residues: PEGylation of G-CSF at lysine-41. POLYMER CHEMISTRY, vol. 7, p. 6545-6553
11. Mero Anna, Campisi Monica, Caputo Michele, Cuppari Christian, Rosato Antonio, Schiavon Oddone, Pasut Gianfranco (2015). Hyaluronic acid as a protein polymeric carrier: An overview and a report on human growth hormone. CURRENT DRUG TARGETS, vol. 16, p. 1503-1511
12. Pasut G, Paolino D, Celia C, Mero A, Joseph AS, Wolfram J, Cosco D, Schiavon O, Shen H, Fresta M (2014). Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. JOURNAL OF CONTROLLED RELEASE, vol. 199, p. 106-113
13. Anna Mero, Monica Campisi, Marta Favero, Carlo Barbera, Cynthia Secchieri, Jean M. Dayer, Mary B. Goldring, Steven R. Goldring, Gianfranco Pasut (2014). A hyaluronic acid-salmon calcitonin conjugate for the local treatment of osteoarthritis: Chondro-protective effect in a rabbit model of early OA. JOURNAL OF CONTROLLED RELEASE, vol. 187, p. 30-38

Area di ricerca

Nanomedicines have developed rapidly and their use is changing the world of medicine, leading to improved drug efficacy, fewer side effects and better patient compliance. Personalized nanomedicines are expected to be the future of clinical practice, but some aspects such as the development of feasible drug delivery systems must be solved before their use can be upscaled. An intense collaboration with pharmaceutical industries is necessary to ensure a balance between innovation and feasibility.
The aim of a drug delivery system is to increase the effectiveness of therapeutic protocols and at the same time to reduce toxicity and overall treatment costs. Out of the array of drug delivery approaches available, polymer conjugation is emerging because of its applicability to both low MW drugs and proteins. A water soluble polymer can confer several properties to linked molecules: i) increased half-life due to reduced kidney clearance, ii) protection against degrading enzymes or reduced uptake by reticulo-endothelial system (RES), thanks to the polymer steric hindrance iii) augmentation of water solubility, particularly relevant for some anticancer drugs with low solubility, iv) prevention of immunogenicity of heterologous proteins and v) selective tumour accumulation, coined, the ‘enhanced permeability and retention’ (EPR) effect which does not apply to low molecular weight drugs, which freely extravasate also from the normal vessels of healthy tissues, thus causing general toxicity.
My research focuses on two streams of study dealing with:
a) Polymer-drug conjugates
Over the past three decades, cancer research has not only been focused on understanding the molecular basis of cancer and in testing new small organic compounds but also in studying and exploring the potential of drug delivery systems.
Poly(ethylene glycol) (PEG) has a particular structure with only two functionalizable groups, which makes it possible to prepare conjugates with a precise chemical structure. We developed several high loading PEGs by synthesizing the dendron structure at one or both of the polymer’s ends. Those new polymers offer great control over the number of drug molecules coupled per polymer chain, and when an heterobifunctional PEG is used it is also possible to create well defined conjugates with the desired ratio between the polymer:drug:targeting agent. Other polymers are also studies, such as hyaluronic acid polyglutamic acid polysialic acid, poly(2-N-ethyl oxazoline), etc.
b) Polymer-protein conjugates
The rationale behind polymer conjugation is to prolong the plasma half-life of therapeutically active agents by increasing their hydrodynamic volume and hence reducing the kidney excretion rate. Polymer chains can, moreover, inhibit the approach of antibodies, proteolytic enzymes or cells on the surface of conjugated proteins, an effect obtained by steric hindrance of polymer chains.
We have developed several PEGs conjugates with therapeutic proteins, such as human growth hormone (hGH), granulocyte colony stimulating factor, asparaginase, interferon alpha, salmon calcitonin, insulin and a PEG-hGH conjugate has been tested in monkeys.
Researches are also focused on the study of microbial transglutaminase (mTGase) as an enzyme for enzymatic polymer conjugation. mTGase-mediated PEGylation presents two important advantages: i) the modification of glutamine, a residue that otherwise cannot be modified with chemical methods and ii) the enzyme selectivity.

Tesi proposte

Proposed thesis are focused on the research aims presented in the "Research Area" section.
Pasut has several international collaborations that can be taken into consideration for the thesis subject.